Latest Articles

Publication Date
All News Scientific
Exclusive BAC Article: Faeth Therapeutics; Year-End 2026 PIKTOR Endometrial Cancer Data, Breast Cancer Interim Results 2027, Solid Tumor Expansions, And Catalysts (NASDAQ:FTH) - Seeking Alpha

Exclusive BAC Article: Faeth Therapeutics; Year-End 2026 PIKTOR Endometrial Cancer Data, Breast Cancer Interim Results 2027, Solid Tumor Expansions, And Catalysts (NASDAQ:FTH) Seeking Alpha

Published: Aug. 17, 2026, 7:11 p.m.
Read Full Article
Faeth Therapeutics Announces FDA Grant of Fast Track Designation for PIKTOR Plus Paclitaxel in Biomarker-Selected Advanced Endometrial Cancer - BioSpace

Faeth Therapeutics Announces FDA Grant of Fast Track Designation for PIKTOR Plus Paclitaxel in Biomarker-Selected Advanced Endometrial Cancer BioSpace

Published: Aug. 17, 2026, 1:47 p.m.
Read Full Article
Faeth Therapeutics (FTH) Gains FDA Fast Track for Endometrial Ca - GuruFocus

Faeth Therapeutics (FTH) Gains FDA Fast Track for Endometrial Ca GuruFocus

Published: Aug. 17, 2026, 12:03 p.m.
Read Full Article
Faeth Therapeutics (FTH) Gains FDA Fast Track for Endometrial Cancer Combo Therapy - GuruFocus

Faeth Therapeutics (FTH) Gains FDA Fast Track for Endometrial Cancer Combo Therapy GuruFocus

Published: Aug. 17, 2026, 12:03 p.m.
Read Full Article
Faeth Therapeutics Announces FDA Grant of Fast Track Designation for PIKTOR Plus Paclitaxel in Biomarker-Selected Advanced Endometrial Cancer - Business Wire

Faeth Therapeutics Announces FDA Grant of Fast Track Designation for PIKTOR Plus Paclitaxel in Biomarker-Selected Advanced Endometrial Cancer Business Wire

Published: Aug. 17, 2026, 11:30 a.m.
Read Full Article
Integrated lipidomics and transcriptomics reveal the key role of ceramides in the development of endometriosis.

Endometriosis (EMs) is a chronic gynecological disease with poorly understood pathogenesis. This study integrated lipidomics and transcriptomics to systematically investigate aberrant sphingolipid metabolism in EMs, aiming to identify pathogenic mechanisms …

Published: Aug. 11, 2026, midnight
Read Full Article
Ceramide Endometriosis Lipidomics Macrophage SMPD3 Sphingolipid metabolism Sphingomyelinase
Faeth Therapeutics to Present PK/PD Modeling That Informed PIKTOR Dose Selection in Ongoing FTH-PIK-201 Trial at Upcoming Scientific Conference - BioSpace

Faeth Therapeutics to Present PK/PD Modeling That Informed PIKTOR Dose Selection in Ongoing FTH-PIK-201 Trial at Upcoming Scientific Conference BioSpace

Published: Aug. 7, 2026, 12:17 p.m.
Read Full Article
Whitehawk Therapeutics reports Q2 2026 net loss $16.6M; cash $190.0M funds into 2H 2028 - TradingView

Whitehawk Therapeutics reports Q2 2026 net loss $16.6M; cash $190.0M funds into 2H 2028 TradingView

Published: Aug. 6, 2026, 2:13 p.m.
Read Full Article
Opal Therapeutics Secures $1.25M NSF SBIR Phase II Award to Accelerate Women’s Health Drug Discovery - Business Wire

Opal Therapeutics Secures $1.25M NSF SBIR Phase II Award to Accelerate Women’s Health Drug Discovery Business Wire

Published: Aug. 6, 2026, 10:30 a.m.
Read Full Article
Opal Therapeutics Secures $1.25M NSF SBIR Phase II Award to Accelerate Women’s Health Drug Discovery - businesswire.com

Opal Therapeutics Secures $1.25M NSF SBIR Phase II Award to Accelerate Women’s Health Drug Discovery businesswire.com

Published: Aug. 6, 2026, 10:30 a.m.
Read Full Article
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!